Repligen (RGEN) Tops Q1 EPS by 2c; Raises Outlook
Get Alerts RGEN Hot Sheet
Revenue Growth %: -17.9%
Financial Fact:
(Loss) income from operations: 3.75M
Today's EPS Names:
SHIM, KOD, HEWA, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q1 EPS of $0.12, $0.02 better than the analyst estimate of $0.10. Revenue for the quarter came in at $25.1 million versus the consensus estimate of $22.54 million.
Tony J. Hunt, President and Chief Executive Officer, said, “Our record revenue during the first quarter reflects overall growth of 21% year-over-year, driven by increased demand for our proprietary products, which we believe is a direct result of our commercial expansion in 2015. We continue to add best-in-class technologies to our portfolio, and we closed out the quarter by executing on our acquisition strategy with our April 1st purchase of Atoll GmBH (“Atoll”). We are pleased with how the integration is progressing and look forward to establishing the Weingarten, Germany, facility as our European customer-facing center for many of our high-value products.”
GUIDANCE:
Repligen sees FY2016 EPS of $0.45-$0.51, versus the consensus of $0.43. Repligen sees FY2016 revenue of $98-102 million, versus prior guidance of $93-96 million and the consensus of $96.77 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Can-Fite BioPharma (CANF) Reports FY23 Results, Issues Clinical Update
- China Automotive Systems (CAAS) Tops Q4 EPS by 24c ; Offers Guidance
- Stran & Company, Inc. (SWAG) Misses Q4 EPS by 1c
Create E-mail Alert Related Categories
Earnings, Guidance, Management CommentsRelated Entities
Earnings, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!